News und Analysen
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper.
Three Motley Fool
Is Geron Stock a Buy Following Its First New Drug Approval?
Shares of Geron (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades.
On June 6, the U.S. Food
U.S. Rep. Thomas Kean Jr. Just Bought Illumina Stock and Sold Nike Stock. Should You Do the Same?
On April 19, U.S. Rep. Thomas Kean Jr., R-N.J., bought shares of Illumina (NASDAQ: ILMN) and sold shares of Nike (NYSE: NKE), according to a May 31 filing. Although it's unclear exactly how many
U.S. Rep. Thomas Kean Jr. Just Bought Illumina Stock and Sold Nike Stock. Should You Do the Same?
On April 19, U.S. Rep. Thomas Kean Jr., R-N.J., bought shares of Illumina (NASDAQ: ILMN) and sold shares of Nike (NYSE: NKE), according to a May 31 filing. Although it's unclear exactly how many
U.S. Rep. Thomas Kean Jr. Just Bought Illumina Stock and Sold Nike Stock. Should You Do the Same?
On April 19, U.S. Rep. Thomas Kean Jr., R-N.J., bought shares of Illumina (NASDAQ: ILMN) and sold shares of Nike (NYSE: NKE), according to a May 31 filing. Although it's unclear exactly how many
2 Dividend Stocks Billionaires Are Buying: Should You?
Many billionaires are active on Wall Street and largely built their wealth that way. So, paying attention to their moves and the stocks they invest in can teach us a lot. Of course, blindly
2 Dividend Stocks Billionaires Are Buying: Should You?
Many billionaires are active on Wall Street and largely built their wealth that way. So, paying attention to their moves and the stocks they invest in can teach us a lot. Of course, blindly
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood doesn't take any trading days off. The co-founder and CEO of Ark Invest publishes her transactions for the family of exchange-traded funds she manages. She didn't make a lot of moves on
Medtronic Raised Its Dividend for a 47th Straight Year, But Here's Why It Isn't a Great Dividend Growth Stock
Dividend growth stocks can make for excellent long-term investments. Their ongoing rate increases allow investors to generate more in dividend income than if they were to just invest in a stale
Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics (NASDAQ: VKTX) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the metabolic disease specialist has, so far, delivered a staggering 208% return on
Why Things Could Get Worse for Pfizer Stock Before They Get Better
A few years ago, in the race to launch a COVID-19 vaccine, Pfizer (NYSE: PFE) stock was a hot buy after the company ended up with a highly successful product in Comirnaty. The uncertainty
Why Things Could Get Worse for Pfizer Stock Before They Get Better
A few years ago, in the race to launch a COVID-19 vaccine, Pfizer (NYSE: PFE) stock was a hot buy after the company ended up with a highly successful product in Comirnaty. The uncertainty
Dexcom G7 Now Connects Directly to Apple Watch in the U.S.
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the Dexcom G7 Continuous Glucose Monitoring (CGM) System now
Dexcom G7 Now Connects Directly to Apple Watch in the U.S.
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the Dexcom G7 Continuous Glucose Monitoring (CGM) System now
Top Stocks to Buy in June
When you look at the stock market, valuations can seem stretched for a lot of the megacap names -- not all -- but there are still plenty of deals to be had. In today's video, I will look into a few
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Pfizer (NYSE: PFE) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock.
Shares of Pfizer have been
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Pfizer (NYSE: PFE) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock.
Shares of Pfizer have been
Nova Scotia Now Providing Coverage for Dexcom Continuous Glucose Monitoring Systems
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, today announced that residents of Nova Scotia living with either type 1 or
Nova Scotia Now Providing Coverage for Dexcom Continuous Glucose Monitoring Systems
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, today announced that residents of Nova Scotia living with either type 1 or
University of Alabama at Birmingham (UAB) Health System and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in Alabama
The University of Alabama at Birmingham (UAB) Health System and Humana, a leading health and well-being company, have signed an in-network agreement, expanding access to care for all Humana
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
Even if you're not an investor like Cathie Wood, who specializes in businesses that claim to have a shot at disrupting their industries, investing in aspiring disruptors can be a great tactic to
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and Wegovy, billions in new revenue inflows are assured in the near term.
But
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and Wegovy, billions in new revenue inflows are assured in the near term.
But